NCT02347813View on ClinicalTrials.gov

Preventing Squamous Cell Skin Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

June 1, 2018

Study Completion Date

June 1, 2019

Conditions
Squamous Cell Carcinoma of the Skin
Interventions
DRUG

Pioglitazone

15 mg of pioglitazone orally for 2 weeks, and if well tolerated, 30 mg pioglitazone orally for 5 1/2 months.

All Listed Sponsors
lead

University of Rochester

OTHER

NCT02347813 - Preventing Squamous Cell Skin Cancer | Biotech Hunter | Biotech Hunter